Patient input into medical research is becoming increasingly important. The MPE Advocate Development Programme aims to help myeloma advocates understand the research and development process of drugs, from the preclinical stages through to post-marketing surveillance and national access. Topics include clinical trial design, regulation, pricing and health technology assessment (HTA). The programme combines a series of theoretical sessions delivered by experts with practical sessions that take place during the most important myeloma scientific meetings in Europe: the European Haematology Association (EHA) Annual Meeting, the European Society of Medical Oncology (ESMO) Annual Meeting and the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual European Congress.
Ananda Plate, CEO of Myeloma Patients Europe, explains in this video the main objectives of this programme:
The MPE Advocate Development Programme is a training programme for myeloma advocates that runs for 12 months every year.
The ADP is mainly an online programme, with online modules and webinars, that is complemented by four face-to-face sessions during EHA (June 14-17, Stockholm, Sweden), ESMO (October 19-23, Munich, Germany), ISPOR (10-14 November, Barcelona, Spain) and an ADP retreat in February.